Companies › Nested Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Nov 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NST-628 non-covalent pan-RAF/MEK dual molecular glue targeting RAF and MEK nodes of MAPK pathway | RAF1, MAP2K1 | Phase 1 | Oncology | Nov 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06326411 | NST-628 | Phase 1 | Oncology | Oncology | Nov 2028 |
Roche Novartis Hanmi Pharmaceutical Company Erasca Bayer Day One Biopharmaceuticals Ipsen AstraZeneca Pierre Fabre Medicament Shanghai Kechow Pharma
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.